Latest & greatest articles for cannabis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cannabis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cannabis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cannabis

61. [Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

[Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Extrakt aus Cannabis Sativa – Nutzenbewertung gemäß § 35a SGB V [Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Extrakt aus Cannabis Sativa – Nutzenbewertung gemäß § 35a SGB V [Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Extrakt aus Cannabis Sativa – Nutzenbewertung gemäß § 35a SGB V. [Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG Berichte 124. 2012 Final publication URL Indexing

Health Technology Assessment (HTA) Database.2012

62. Delusional-like experiences are more common in those with cannabis dependence disorder, very early-onset alcohol use or dependence disorders, and daily smokers

Delusional-like experiences are more common in those with cannabis dependence disorder, very early-onset alcohol use or dependence disorders, and daily smokers Delusional-like experiences are more common in those with cannabis dependence disorder, very early-onset alcohol use or dependence disorders, and daily smokers | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Delusional-like experiences are more common in those with cannabis dependence disorder, very early-onset alcohol use or dependence disorders, and daily smokers Article Text

Evidence-Based Mental Health2012

63. What is the Accuracy of Screening Instruments for Alcohol and Cannabis Misuse Disorders Among Adolescents and Young Adults in the Emergency Department?

What is the Accuracy of Screening Instruments for Alcohol and Cannabis Misuse Disorders Among Adolescents and Young Adults in the Emergency Department? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2012

64. Extract from Cannabis sativa - Benefit assessment according to § 35a Social Code Book V

Extract from Cannabis sativa - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment (“Extrakt aus Cannabis Sativa – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status: 29.03.2012). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract from Cannabis sativa – Benefit assessment (...) according to § 35a Social Code Book V 1 Extract of dossier assessment A12-01 Version 1.0 Extract from Cannabis sativa – Benefit assessment acc. to § 35a SGB V 29.03.2012 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Extract from Cannabis sativa – Benefit assessment according to § 35a Social Code Book V Contracting agency: Federal Joint Committee Commission awarded on: 02.01.2012 Internal

Institute for Quality and Efficiency in Healthcare (IQWiG)2012

65. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study.

Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. OBJECTIVE: To determine whether use of cannabis in adolescence increases the risk for psychotic outcomes by affecting the incidence and persistence of subclinical expression of psychosis in the general population (that is, expression of psychosis below the level required for a clinical diagnosis). DESIGN: Analysis of data from a prospective population based cohort study in Germany (...) (early developmental stages of psychopathology study). SETTING: Population based cohort study in Germany. PARTICIPANTS: 1923 individuals from the general population, aged 14-24 at baseline. MAIN OUTCOME MEASURE: Incidence and persistence of subthreshold psychotic symptoms after use of cannabis in adolescence. Cannabis use and psychotic symptoms were assessed at three time points (baseline, T2 (3.5 years), T3 (8.4 years)) over a 10 year follow-up period with the Munich version of the composite

BMJ2011 Full Text: Link to full Text with Trip Pro

66. Incident cannabis use in adolescents and young adults is associated with an increased risk of developing psychotic symptoms

Incident cannabis use in adolescents and young adults is associated with an increased risk of developing psychotic symptoms Incident cannabis use in adolescents and young adults is associated with an increased risk of developing psychotic symptoms | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Incident cannabis use in adolescents and young adults is associated with an increased risk of developing psychotic symptoms Article Text Prognosis Incident cannabis use in adolescents and young adults is associated with an increased risk of developing

Evidence-Based Mental Health2011

67. Cannabis and suicide: longitudinal study

Cannabis and suicide: longitudinal study 19949196 2009 12 01 2010 03 10 2009 12 01 1472-1465 195 6 2009 Dec The British journal of psychiatry : the journal of mental science Br J Psychiatry Cannabis and suicide: longitudinal study. 492-7 10.1192/bjp.bp.109.065227 Some studies suggest that cannabis use is associated with suicidal ideation, but no detailed longitudinal study has examined suicide as an outcome. To examine the association between cannabis use and completed suicide. A longitudinal (...) study investigated 50 087 men conscripted for Swedish military service, with cannabis use measured non-anonymously at conscription. Suicides during 33 years of follow-up were identified by linkage with the National Cause of Death Register. There were 600 (1.2% of cohort) suicides or deaths from undetermined causes. Cannabis use was associated with an increased risk of suicide (crude OR for 'ever use' 1.62, 95% CI 1.28-2.07), but this association was eliminated after adjustment for confounding

EvidenceUpdates2010

68. Review: pharmacological and psychological interventions decrease cannabis use in people with depressive and psychotic disorders in the short term

Review: pharmacological and psychological interventions decrease cannabis use in people with depressive and psychotic disorders in the short term Review: pharmacological and psychological interventions decrease cannabis use in people with depressive and psychotic disorders in the short term | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: pharmacological and psychological interventions decrease cannabis use in people with depressive and psychotic disorders in the short term Article Text Therapeutics Review: pharmacological and psychological

Evidence-Based Mental Health2010

69. A meta-analytic review of school-based prevention for cannabis use

A meta-analytic review of school-based prevention for cannabis use A meta-analytic review of school-based prevention for cannabis use A meta-analytic review of school-based prevention for cannabis use Porath-Waller AJ, Beasley E, Beirness DJ CRD summary The authors appeared to conclude that school-based prevention programmes reduced youth cannabis use, especially programmes that used mixed models, had longer duration and were facilitated by non-teachers who used interactive methods. In view (...) of limitations in the review, which included poor reporting of study characteristics, heterogeneity between studies and extensive data manipulation, these conclusions should be interpreted with caution. Authors' objectives To evaluate the effectiveness of school-based prevention programmes for reducing cannabis use in 12 to 19 year olds. Searching PsycINFO, PubMed, EMBASE, ERIC, Education, Health Sciences, Sociological Abstracts and BHI: British Humanities Index (CSA Illumina) were searched from 1999 to 2007

DARE.2010

71. Estimates of how many cannabis users need to be prevented in order to prevent one case of schizophrenia

Estimates of how many cannabis users need to be prevented in order to prevent one case of schizophrenia Estimates of how many cannabis users need to be prevented in order to prevent one case of schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Estimates of how many cannabis users need to be prevented in order to prevent one case of schizophrenia Article Text Aetiology Estimates of how many cannabis users need to be prevented in order to prevent one case of schizophrenia Statistics from Altmetric.com No Altmetric data available

Evidence-Based Mental Health2010

72. Review: short-term medical use of cannabis increases risk of non-serious adverse effects

Review: short-term medical use of cannabis increases risk of non-serious adverse effects Review: short-term medical use of cannabis increases risk of non-serious adverse effects | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: short-term medical use of cannabis increases risk of non-serious adverse effects Article Text Treatment Review: short-term medical use of cannabis increases risk of non-serious adverse effects Statistics from Altmetric.com No Altmetric data available for this article. M

Evidence-Based Nursing (Requires free registration)2010

73. Adverse health effects of non-medical cannabis use.

Adverse health effects of non-medical cannabis use. For over two decades, cannabis, commonly known as marijuana, has been the most widely used illicit drug by young people in high-income countries, and has recently become popular on a global scale. Epidemiological research during the past 10 years suggests that regular use of cannabis during adolescence and into adulthood can have adverse effects. Epidemiological, clinical, and laboratory studies have established an association between cannabis (...) use and adverse outcomes. We focus on adverse health effects of greatest potential public health interest-that is, those that are most likely to occur and to affect a large number of cannabis users. The most probable adverse effects include a dependence syndrome, increased risk of motor vehicle crashes, impaired respiratory function, cardiovascular disease, and adverse effects of regular use on adolescent psychosocial development and mental health.

Lancet2009

74. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review Lakhan SE, Rowland M CRD summary This review concluded that there was evidence that combined extracts of cannabis (delta 9 -tetrahydrocannabinol and cannabidiol) may provide therapeutic (...) benefit for spasticity symptoms in patients with multiple sclerosis. In light of the good quality of the included trials, the authors' cautious conclusions appear to be appropriate, although the small number of trials should be borne in mind. Authors' objectives To assess the efficacy of whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis. Searching MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for published English-language studies

DARE.2009

75. Systematic review and meta-analysis of cannabis treatment for chronic pain

Systematic review and meta-analysis of cannabis treatment for chronic pain Systematic review and meta-analysis of cannabis treatment for chronic pain Systematic review and meta-analysis of cannabis treatment for chronic pain Martin-Sanchez E, Furukawa TA, Taylor J, Martin JL CRD summary This review concluded that cannabis treatment was moderately efficacious for the treatment of chronic pain, but the risk of potentially serious harms may offset any treatment benefit. The authors' conclusion (...) reflected the evidence presented, but the extent to which it is reliable is potentially compromised by an incompletely reported review process and reliance on trials of less than optimal quality. Authors' objectives To evaluate the efficacy and harms of cannabis preparations in the treatment of patients with chronic pain. Searching PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched, with no language restriction, to February 2008. Search terms were reported

DARE.2009

77. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia

Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia 18981338 2008 11 04 2008 11 18 2008 11 04 1538-3636 65 11 2008 Nov Archives of general psychiatry Arch. Gen. Psychiatry Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. 1269-74 10.1001/archpsyc.65.11.1269 Cannabis-induced psychosis is considered a distinct clinical entity (...) in the existing psychiatric diagnostic systems. However, the validity of the diagnosis is uncertain. To establish rate ratios of developing cannabis-induced psychosis associated with predisposition to psychosis and other psychiatric disorders in a first-degree relative and to compare them with the corresponding rate ratios for developing schizophrenia spectrum disorders. A population-based cohort was retrieved from the Danish Psychiatric Central Register and linked with the Danish Civil Registration System

EvidenceUpdates2008

78. Cannabis and schizophrenia.

Cannabis and schizophrenia. BACKGROUND: Many people with schizophrenia use cannabis and its effects on the illness are unclear. OBJECTIVES: To evaluate the effects of cannabis use on people with schizophrenia and schizophrenia-like illnesses. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. SELECTION CRITERIA: We included all randomised trials involving (...) cannabinoids and people with schizophrenia or schizophrenia-like illnesses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis, based on a fixed effects model. We calculated the numbers needed to treat/harm (NNT/NNH). For continuous data, we calculated weighted mean differences (WMD) again based on a fixed effects model. MAIN RESULTS: We identified one randomised trial

Cochrane2008

79. Cannabis use increases risk of developing symptoms of mania

Cannabis use increases risk of developing symptoms of mania Cannabis use increases risk of developing symptoms of mania | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cannabis use increases risk of developing symptoms of mania Article Text Aetiology Cannabis use increases risk of developing symptoms of mania Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service

Evidence-Based Mental Health2008

80. Cannabis smoking and periodontal disease among young adults.

Cannabis smoking and periodontal disease among young adults. CONTEXT: Tobacco smoking is a recognized behavioral risk factor for periodontal disease (through its systemic effects), and cannabis smoking may contribute in a similar way. OBJECTIVE: To determine whether cannabis smoking is a risk factor for periodontal disease. DESIGN AND SETTING: Prospective cohort study of the general population, with cannabis use determined at ages 18, 21, 26, and 32 years and dental examinations conducted (...) to 32 years) determined from periodontal combined attachment loss (CAL) measured at 3 sites per tooth. RESULTS: Three cannabis exposure groups were determined: no exposure (293 individuals, or 32.3%), some exposure (428; 47.4%), and high exposure (182; 20.2%). At age 32 years, 265 participants (29.3%) had 1 or more sites with 4 mm or greater CAL, and 111 participants (12.3%) had 1 or more sites with 5 mm or greater CAL. Incident attachment loss between the ages of 26 and 32 years in the none, some

JAMA2008 Full Text: Link to full Text with Trip Pro